Frequently Asked Questions

In these pharmacokinetic simulations, LY03010 351 mg every 4 weeks produced substantially higher steady-state paliperidone exposure than standard monthly PP1M 234 mg and was comparable to PP1M 234 mg every 3 weeks. With deltoid maintenance injections, median steady-state average concentration (Cavg,ss) was 76.3 [42, 133] ng/mL for LY03010 351 mg every 4 weeks versus 50.9 [25.8, 95.4] ng/mL for IS 234 mg every 4 weeks and 67.3 [33.9, 124] ng/mL for IS 234 mg every 3 weeks. The authors state that this suggests LY03010 351 mg every 4 weeks may be an alternative option for patients with schizophrenia or schizoaffective disorder who have an inadequate response to standard 234 mg every 4 weeks, but they also note that no controlled clinical data currently support this off-label regimen.

Yes. In the simulations, LY03010 351 mg every 6 weeks gave steady-state paliperidone exposure very similar to IS 234 mg every 4 weeks. For LY03010 using the approved initiation regimen followed by every-6-week deltoid maintenance dosing, median [90% prediction interval] Cmax,ss was 67.9 [41.3, 108] ng/mL, Ctrough,ss was 34.5 [11.9, 74.2] ng/mL, and Cavg,ss was 51.7 [28.8, 89.5] ng/mL. The corresponding values for IS 234 mg every 4 weeks were 66.3 [37.3, 113] ng/mL, 39 [13.7, 84.7] ng/mL, and 50.9 [25.8, 95.4] ng/mL, respectively.

The discussion notes that the slightly lower trough concentration with LY03010 351 mg every 6 weeks is not expected to be clinically meaningful.

LY03010 351 mg every 8 weeks did not match a single monthly PP1M dose; instead, its steady-state exposure fell between higher and lower monthly regimens. With the approved initiation regimen followed by every-8-week deltoid maintenance dosing, median [90% prediction interval] Cmax,ss was 57.8 [35.6, 91.6] ng/mL and Cavg,ss was 39.3 [21.7, 67] ng/mL, which were between IS 234 mg every 4 weeks and IS 156 mg every 4 weeks. Its Ctrough,ss was 20.6 [5.25, 49.9] ng/mL, which was comparable to IS 117 mg every 4 weeks at 19.6 [6.85, 42.5] ng/mL.

In these simulations, deltoid and gluteal maintenance injections produced similar steady-state paliperidone exposure for LY03010 351 mg. The authors report no noticeable difference in exposure between deltoid and gluteal administration for the every-4-week regimen, and similar exposure across injection sites for the every-6-week and every-8-week regimens as well. This was consistent whether maintenance dosing began 4 weeks after the first injection or continued on an ongoing every-6-week or every-8-week schedule.

The higher-exposure every-4-week regimen increased the proportion of simulated patients whose steady-state peak concentration exceeded 120 ng/mL, a laboratory alert level for paliperidone. Approximately 18.5% of subjects with LY03010 351 mg every 4 weeks in the deltoid and 16.2% with gluteal administration had Cmax,ss above 120 ng/mL, compared with 12.6% for IS 234 mg every 3 weeks. The authors advise close monitoring for potential side effects when using higher paliperidone palmitate doses, including extrapyramidal symptoms and prolactin levels.

This was a population pharmacokinetic modeling and simulation study, not a controlled clinical efficacy trial. The model was built from 5,731 plasma paliperidone concentrations obtained in 276 subjects from 2 phase 1 studies in patients with schizophrenia or schizoaffective disorder. Using that model, the investigators simulated exposure outcomes such as steady-state average, peak, and trough concentrations for alternative LY03010 and IS dosing schedules.

The article reports that the population pharmacokinetic model performed well against observed data. It used a 1-compartment open model with sequential zero-order and first-order absorption processes, and the visual predictive check showed that the simulated 5th, 50th, and 95th percentiles matched the observed concentrations well across both studies and time periods. The authors also state that diagnostic plots indicated the model adequately described the observed data and was unbiased, and bootstrap-derived 95% confidence intervals were in good agreement with parameter estimates.

The main limitation is that these were simulated pharmacokinetic exposures without controlled clinical outcome data for the alternative regimens. The authors specifically state that no controlled clinical data are currently available to support these off-label dosing strategies. As a result, the findings suggest possible dosing options based on modeled exposure, but caution is warranted when considering off-label use of paliperidone palmitate.